IP Library › Granted Patent US 11,267,883
Granted Patent B2
US 11,267,883 · App. 16/471,616 · Granted Mar 8, 2022

Antibodies that specifically bind to human IL-15 and uses thereof

Inventors: David Jose Simon Laine (Macquarie Park, AU); Matthew Pollard (Pullenvale, AU); Anthony Gerard Doyle (Macquarie Park, AU); Lynn Dorothy Poulton (Macquarie Park, AU); Adam William Clarke (Macquarie Park, AU)
Assignee: Cephalon, Inc.
C07K16/244A61P1/00A61P3/00A61P29/02A61P37/00A61K2039/505C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,267,883
App. No.
16/471,616
Granted
Mar 8, 2022
Kind
B2
Abstract

Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

Claims (27)

1. An antibody that specifically binds to human IL-15, wherein the IL-15 is complexed with IL-15 Receptor alpha (IL-15Rα), and wherein the antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 16, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 17, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 20, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 25, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 29.

2. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO: 18.

3. The antibody according to claim 1 wherein the antibody comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 26 and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 30.

4. The antibody according to claim 3 , wherein the antibody comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 454 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

5. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO: 19, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 27, an LCDR3 comprising the amino acid sequence of SEQ ID NO: 31, and a heavy chain FR3 comprising the amino acid sequence of SEQ ID NO: 14.

6. The antibody according to claim 5 , wherein the antibody comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

7. The antibody of claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.

8. The antibody according to claim 1 , wherein the antibody binds to an epitope comprising the Q108 residue of human IL-15.

9. A composition, comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier or excipient.

10. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:30.

11. A composition comprising the antibody according to claim 10 and a pharmaceutically acceptable carrier or excipient.

12. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 27 and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 31.

13. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO:18, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 26, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 31.

14. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO:18, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 30.

15. The antibody according to claim 1 , wherein the antibody comprises an HCDR2 comprising the amino acid sequence of SEQ ID NO:18, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 519.

16. The antibody according to claim 1 , wherein the antibody comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 455.

17. The antibody according to claim 1 , wherein the antibody comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 457.

18. The antibody according to claim 1 , wherein the antibody comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and (ii) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 459.

19. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

20. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:510.

21. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:455.

22. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:457.

23. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:506.

24. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:5.

25. The antibody according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:454 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:510.

26. An antibody that binds to IL-15 wherein the IL-15 is complexed with IL-15 Receptor alpha (IL-15Rα), comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 5.

27. A method of treating Celiac disease in a subject in need thereof, comprising administering to the subject the antibody according to claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jun 29, 2023
From: CEPHALON, INC.
To: CEPHALON LLC
Reel/Frame 064176/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2020
From: LAINE, DAVID JOSE SIMON; POLLARD, MATTHEW; DOYLE, ANTHONY GERARD; POULTON, LYNN DOROTHY; CLARKE, ADAM WILLIAM
To: CEPHALON, INC.
Reel/Frame 052675/0696 →
Continuity (2)
Provisional Application 62437143 · Dec 21, 2016
Related Publication 20200270339A1 · Aug 27, 2020
Cited By (3)
US 12,459,980 US 12,600,762 US 12,600,788